Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine α1A-adrenoceptors antagonists using GALAHAD

Journal of Molecular Graphics and Modelling

Volumn 29, Issue 2, 2010, Pages 126-136

  Zhao, Xin ^a,b   Yuan, Mu ^a   Huang, Biyun ^a   Ji, Hong ^a   Zhu, Liu ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGDONG INDUSTRY TECHNICAL COLLEGE   (China)

Author keywords

1A Adrenoceptors antagonists; Activity predicting; CoMFA; GALAHAD; Ligand based drug design; N Aryl and N Heteroaryl piperazine; Pharmacophore models

Indexed keywords

ACTIVITY PREDICTING; COMFA; GALAHAD; N-ARYL AND N-HETEROARYL PIPERAZINE; PHARMACOPHORE MODELS;

FORECASTING; LIGANDS; MOLECULAR GRAPHICS; OPTIMIZATION; PHARMACODYNAMICS; ZINC;

THREE DIMENSIONAL;

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; DATA ANALYSIS SOFTWARE; DATA BASE; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; LIGANDS; MODELS, MOLECULAR; PIPERAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ADRENERGIC, ALPHA-1; SOFTWARE;

EID: 77956283364     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2010.05.002     Document Type: Article

References (34)

1. Tiwari A., Krishna N.S., Nanda K., Chugh A. Benign prostatic hyperplasia: an insight into current investigational medical therapies. Exp. Opin. Invest. Drugs 2005, 14:1359-1372.
2. Natasha K., Juan P.L., Andrew B., Richard A., Stephen C.J. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol. 1998, 159:1810-1815.
3. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Atlas. Urol. Clin. 1990, 17:641-649.
4. 1-Adrenoceptor subtypes. Eur. J. Pharmacol. 1999, 375:261-276.
5. Kaplan S. α-Blocker therapy: current update. Rev. Urol. 2005, 7:S34-S42.
6. 1-adrenoreceptor antagonists as antihypertensive agents. Bioorg. Med. Chem. 2008, 16:4759-4800.
7. 1 adrenoceptor subtype selective antagonists. Bioorg. Med. Chem. 2000, 8:201-214.
8. 1A-adrenoceptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15:657-664.
9. 1-adrenoceptor subtypes. J. Mol. Graph. Model. 2006, 25:146-157.
10. Richmond N.J., Abrams C.A., Wolohan P.R., Abrahamian E., Willett P., Clark R.D. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput. Aided Mol. Des. 2006, 20:567-587.
11. Klabunde T., Evers A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem 2005, 6:876-889.
12. 1a-adrenergic receptor antagonists. J. Med. Chem. 2000, 43:2183-2195.
13. 1a-adrenergic receptor antagonist. Bioorg. Med. Chem. 2000, 8:2263-2275.
14. 1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia. Eur. J. Pharmacol. 2009, 607:213-219.
15. 1a-adrenergic receptor subtype-selective antagonists. J. Pharmacol. Exp. Ther. 2000, 294:224-229.
16. 1a adrenergic antagonists. Bioorg. Med. Chem. Lett. 2002, 12:2443-2446.
17. 1A receptors. Chem. Med. Chem. 2009, 4:393-399.
18. 1-adrenergic receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10:2375-2377.
19. 1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia. Drugs Future 2001, 26:757.
20. Khatuya H., Pulito V.L., Jolliffe L.K., Li X., Murray W.V. Novel thiophene derivatives for the treatment of benign prostatic hyperplasia. Bioorg. Med. Chem. Lett. 2002, 12:2145-2148.
21. Menziani M.C., Montorsi M., De Benedetti P.G., Karelson M. Relevance of theoretical molecular descriptors in quantitative structure-activity relationship analysis of alpha1-adrenergic receptor antagonists. Bioorg. Med. Chem. 1999, 7:2437-2451.
22. 1-adrenoceptor ligands. J. Med. Chem. 2005, 48:2420-2431.
23. 1d adrenergic receptor. J. Med. Chem. 2004, 47:1900-1918.
24. Dror O., Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. Novel approach for efficient pharmacophore-based virtual screening: method and applications. J. Chem. Inf. Model. 2009, 49:2333-2343.
25. 1-adrenergic receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10:1093-1096.
26. Wold S. Validation of QSAR's. Quant. Struct. Act. Relat. 1991, 10:191-193.
27. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110:5959-5967.
28. Cottrell S.J., Gillet V.J., Taylor R., Wilton D.J. Generation of multiple pharmacophore hypotheses using multiobjective optimisation techniques. J. Comput. Aided Mol. Des. 2004, 18:665-682.
29. GALAHAD® Manual, SYBYL, version 8.1, Tripos Inc., Louis, USA, 2008.
30. 1-adrenoceptor binding properties of new arylpiperazine derivatives bearing a flavone nucleus as the terminal heterocyclic molecular portion. Bioorg. Med. Chem. 2004, 12:1527-1535.
31. 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 1996, 35:14312-14317.
32. 1-adrenoceptor. J Mol Struct: Theochem. 1995, 331:79-93.
33. Venturelli P., Menziani M.C., Cocchi M., Fanelli F., de Benedetti P.G. Molecular modelling and quantitative structure-activity relationship analysis using theoretical descriptors of. J Mol Struct: Theochem. 1992, 276:327-340.
34. Kirchmair J., Markt P., Distinto S., Wolber G., Langer T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-What can we learn from earlier mistakes?. J. Comput. Aided Mol. Des. 2008, 22:213-228.